The exit of private equity from their investments in contract research organizations (CROs) could threaten its growth, says two financial experts at Partnerships in Clinical Trials.
Breaking News
Subscribe to VCpost newsletter
Most Popular
- How to Protect Yourself from Check Fraud: Tips and Best Practices
- Mobi: Empowering Consumer Product Companies with Real-time Sales Data
- Exploring the Future of Economic Growth: The Top 5 Special Economic Zones to Watch in 2023
- David Tomassoni (Salvaje): How the Hospitality Industry has Rebounded in the Post-Pandemic World
- How Test Automation Tools are Revolutionizing the Software Development Process
- From Shark Tank to Main Street: Kevin Harrington’s New Fintech Platform is Making Investing in Small Businesses Easier Than Ever
- Meet Kelcy Warren: The CEO Behind Energy Transfer
- World TradeX Creates Nft'S And Digital Coins With Intrinsic Value
